3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
3
Thoracic
1
Gynecologic
1
Genitourinary
1
CNS
1
Conditions
Lung Neoplasms
11
Carcinoma, Non-Small-Cell Lung
3
Smoking Cessation
2
Disease
2
Colorectal Neoplasms
2
Solitary Pulmonary Nodule
1
Pulmonary Disease, Chronic Obstructive
1
Prostatic Neoplasms
1
Pancreatic cancer, adult
1
Ovarian Neoplasms
1
Neoplasms
1
Motor Activity
1
Inflammation
1
Glioblastoma
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
24
Nivolumab
19
atezolizumab
9
Specimen Handling
7
Magnetic Resonance Spectroscopy
7
Cyclophosphamide
7
durvalumab
5
Ipilimumab
5
fludarabine
4
Trastuzumab
4
cemiplimab
3
cabozantinib
3
avelumab
3
Sunitinib
3
Biopsy
3
ulixertinib
2
toripalimab
2
tislelizumab
2
spartalizumab
2
sargramostim
2
relatlimab
2
palbociclib
2
lenvatinib
2
epacadostat
2
enzalutamide
2
cyclopropapyrroloindole
2
copanlisib
2
budigalimab
2
aldesleukin
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Hematologic Tests
×
Thoracic
×
Clear all
NCT06717295
2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
6,000 enrolled